PL3752496T3 - Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae - Google Patents

Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae

Info

Publication number
PL3752496T3
PL3752496T3 PL19707677.1T PL19707677T PL3752496T3 PL 3752496 T3 PL3752496 T3 PL 3752496T3 PL 19707677 T PL19707677 T PL 19707677T PL 3752496 T3 PL3752496 T3 PL 3752496T3
Authority
PL
Poland
Prior art keywords
intermediates
preparing
treatment
methods
viral infection
Prior art date
Application number
PL19707677.1T
Other languages
English (en)
Inventor
Kevin McCormack Allan
Amanda Lynn Vandehey
Gediminas BRIZGYS
Sachin DHAR
Ian James DOXSEE
Alex Goldberg
Lars V. Heumann
Zilin Huang
Nathaniel Thomas KADUNCE
Shahrokh Kazerani
Willard Lew
Vinh Xuan NGO
Brian Michael O'KEEFE
Trevor James RAINEY
Benjamin James Roberts
Bing Shi
Dietrich P. Steinhuebel
Winston C. Tse
Anna Michelle WAGNER
Xianghong Wang
Scott Alan Wolckenhauer
Chloe Yuyi WONG
Jennifer R. Zhang
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3752496T3 publication Critical patent/PL3752496T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/65Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50Mandelic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/06Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19707677.1T 2018-02-16 2019-02-15 Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae PL3752496T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862710575P 2018-02-16 2018-02-16
PCT/US2019/018323 WO2019161280A1 (en) 2018-02-16 2019-02-15 Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection

Publications (1)

Publication Number Publication Date
PL3752496T3 true PL3752496T3 (pl) 2023-11-27

Family

ID=65529928

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19707677.1T PL3752496T3 (pl) 2018-02-16 2019-02-15 Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae

Country Status (12)

Country Link
US (5) US10696657B2 (pl)
EP (2) EP4253366A3 (pl)
JP (5) JP7038843B2 (pl)
KR (3) KR102587504B1 (pl)
CN (2) CN116854630A (pl)
AR (1) AR114631A1 (pl)
AU (3) AU2019222559B2 (pl)
CA (4) CA3281991A1 (pl)
ES (1) ES2956288T3 (pl)
PL (1) PL3752496T3 (pl)
TW (4) TW202535848A (pl)
WO (1) WO2019161280A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
EP3597646B1 (en) 2016-08-19 2023-06-21 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
US10696657B2 (en) * 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
EP3849982A1 (en) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP7398448B2 (ja) 2018-10-24 2023-12-14 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395262A1 (en) 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210393633A1 (en) 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210403465A1 (en) 2018-10-29 2021-12-30 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3876942A1 (en) 2018-11-05 2021-09-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
US20220389007A1 (en) 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2021064570A1 (en) 2019-10-01 2021-04-08 VIIV Healthcare UK (No.5) Limited N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
TW202128648A (zh) 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
EP4041729B1 (en) 2019-10-08 2023-09-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
KR20220151655A (ko) 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
WO2021176367A1 (en) 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN115397424A (zh) 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ, インコーポレイテッド Hivウイルス感染症のための治療化合物
CN116285754B (zh) * 2023-04-18 2025-05-09 安徽禾臣新材料有限公司 一种电子显示屏用的吸附垫及其制备工艺
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
TW202511253A (zh) 2023-05-31 2025-03-16 美商基利科學股份有限公司 製備hiv殼體抑制劑之程序
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
CN116675675A (zh) * 2023-06-05 2023-09-01 北京康立生医药技术开发有限公司 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
CN118126057B (zh) * 2024-05-06 2024-07-19 四川大学华西第二医院 一种化合物RCPH及其合成方法、作为比率型pH探针的应用和产品
US20250367386A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240393A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367385A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240387A1 (en) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367382A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
CN118599802B (zh) * 2024-08-08 2024-10-18 爱斯特(成都)生物制药股份有限公司 一种转氨酶、其制备方法、其应用,编码转氨酶的基因,重组质粒,重组菌,制备(s)-3-氨基丁酸的方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017198A (en) 1910-07-13 1912-02-13 Elmore W Bender Electric motor-vehicle.
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
MXPA03000587A (es) 2000-07-21 2004-04-05 Gilead Sciences Inc Profarmacos de analogos de nucleotido de fosfonato y metodos para seleccionar y elaborar los mismos.
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US7196201B2 (en) 2001-06-27 2007-03-27 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
AU2005222056A1 (en) 2004-02-27 2005-09-22 Schering Corporation Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
MX2008001152A (es) 2005-08-05 2008-04-02 Astrazeneca Ab Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
WO2007070826A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
ES2566481T3 (es) 2006-04-12 2016-04-13 Merck Sharp & Dohme Corp. Antagonistas del canal de calcio de tipo T de piridil amida
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
RU2010120671A (ru) 2007-10-24 2011-11-27 Мерк Шарп Энд Домэ Корп. (Us) Гетероциклические фениламидные антагонисты кальциевых каналов т-типа
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
PE20120616A1 (es) 2009-02-25 2012-05-26 Bigtec Private Ltd Sondas y cebadores para la deteccion de chikungunya
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2467380B1 (en) 2009-08-18 2016-11-30 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
HUE032626T2 (en) 2009-08-18 2017-10-30 Ventirx Pharmaceuticals Inc Toll receptor modulator substituted benzoazepines
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
EP2588450B1 (en) 2010-07-02 2017-05-24 Gilead Sciences, Inc. Napht-2-ylacetic acid derivatives to treat aids
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
US20120082658A1 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the Treatment of Allergic Diseases
JP5951615B2 (ja) 2010-10-01 2016-07-13 ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. Tlrアゴニストの治療用途および組み合わせ治療
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
PT2663555T (pt) 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
PL2688403T3 (pl) 2011-03-23 2017-09-29 Trevena, Inc. Ligandy receptora opioidowego oraz sposoby ich stosowania i wytwarzania
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
US8916575B2 (en) 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
PE20141328A1 (es) 2011-08-16 2014-10-04 Gilead Sciences Inc Tenofovir alafenamida hemifumarato
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
CN106957282B (zh) 2011-12-21 2019-08-30 诺维拉治疗公司 B型肝炎抗病毒剂
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
CA2850881C (en) 2012-04-20 2021-02-16 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
MX369417B (es) 2012-08-10 2019-11-07 Janssen Sciences Ireland Uc Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades.
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US9499549B2 (en) 2012-10-10 2016-11-22 Janssen Sciences Ireland Uc Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases
UA118341C2 (uk) 2012-11-16 2019-01-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Гетероциклічні заміщені похідні 2-амінохіназоліну для лікування вірусних інфекцій
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
AR094311A1 (es) 2012-12-27 2015-07-22 Japan Tobacco Inc Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
WO2014110323A1 (en) 2013-01-11 2014-07-17 Johnson Controls Technology Company Vehicle interior component having a wireless charging indicator
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
JP6466433B2 (ja) 2013-10-24 2019-02-06 ビーブ・ヘルスケア・ユーケイ・(ナンバー5)・リミテッドViiV Healthcare UK (No.5) Limited ヒト免疫不全ウイルス複製の阻害剤
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) * 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
WO2016040084A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
EA032430B1 (ru) 2014-12-24 2019-05-31 Джилид Сайэнс, Инк. Конденсированные пиримидины для лечения вич
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
RU2017138972A (ru) 2015-04-23 2019-05-23 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Ингибиторы репликации вируса иммунодефицита человека
JP2018513183A (ja) 2015-04-23 2018-05-24 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
PT3191470T (pt) 2015-07-06 2019-06-05 Gilead Sciences Inc Moduladores de cot e métodos para a sua utilização
EP3597646B1 (en) 2016-08-19 2023-06-21 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体調節剤化合物
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
UY37710A (es) * 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
US10696657B2 (en) 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US10911396B2 (en) 2018-06-28 2021-02-02 Paypal, Inc. Mid-tier messaging system
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection

Also Published As

Publication number Publication date
JP7749642B2 (ja) 2025-10-06
US20220009904A1 (en) 2022-01-13
TWI866322B (zh) 2024-12-11
US11117886B2 (en) 2021-09-14
US20200369647A1 (en) 2020-11-26
JP7038843B2 (ja) 2022-03-18
EP3752496A1 (en) 2020-12-23
KR102587504B1 (ko) 2023-10-11
US20190300505A1 (en) 2019-10-03
AU2024202049A1 (en) 2024-04-18
TW202204320A (zh) 2022-02-01
CA3281991A1 (en) 2025-11-29
EP4253366A2 (en) 2023-10-04
ES2956288T3 (es) 2023-12-18
CA3090280C (en) 2025-11-25
JP2022036173A (ja) 2022-03-04
EP4253366A3 (en) 2023-11-29
AR114631A1 (es) 2020-09-30
US12122765B2 (en) 2024-10-22
KR20200120941A (ko) 2020-10-22
JP7394901B2 (ja) 2023-12-08
CA3175384A1 (en) 2019-08-22
WO2019161280A1 (en) 2019-08-22
CN112055712A (zh) 2020-12-08
KR102847339B1 (ko) 2025-08-19
US11760746B2 (en) 2023-09-19
AU2022202535B2 (en) 2024-01-04
JP2025181990A (ja) 2025-12-11
EP3752496C0 (en) 2023-07-05
CN116854630A (zh) 2023-10-10
US20240101533A1 (en) 2024-03-28
TWI745652B (zh) 2021-11-11
CA3175557A1 (en) 2019-08-22
AU2022202535A1 (en) 2022-05-19
US10696657B2 (en) 2020-06-30
JP7269316B2 (ja) 2023-05-08
CN112055712B (zh) 2023-07-14
JP2022069569A (ja) 2022-05-11
KR20250126866A (ko) 2025-08-25
EP3752496B1 (en) 2023-07-05
TWI823164B (zh) 2023-11-21
US20250100999A1 (en) 2025-03-27
TW201946915A (zh) 2019-12-16
KR20230145536A (ko) 2023-10-17
TW202415641A (zh) 2024-04-16
CA3090280A1 (en) 2019-08-22
AU2019222559B2 (en) 2022-01-20
AU2019222559A1 (en) 2020-08-27
JP2021513983A (ja) 2021-06-03
JP2024009280A (ja) 2024-01-19
TW202535848A (zh) 2025-09-16

Similar Documents

Publication Publication Date Title
EP3752496C0 (en) METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF VIRAL INFECTION BY RETROVIRIDAE
IL269927A (en) Methods of treating patients with hepatitis B virus infection
IL290999A (en) hbv vaccines and hbv treatment methods
IL292810A (en) Therapeutic compounds and methods of use
IL284047A (en) Combined treatment of HBV
EP3773753A4 (en) TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
IL287423A (en) Antibodies and methods for treating influenza E infection
IL291601B1 (en) Neoglycoconjugates as vaccines and therapeutic tools
IL272094A (en) Antibodies and methods for the diagnosis and treatment of hepatitis B virus infection
IL279078A (en) Combination therapy for the treatment of hepatitis B viral infection
GB201803197D0 (en) Viral treatment
HUE069820T2 (hu) Nalfurafin alkalmazása demielinizációs betegségek kezelésére
HK40095795A (zh) 用於制备可用於治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
DK4054582T3 (da) Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
PL3810625T3 (pl) Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b
PL4010302T3 (pl) Mieszanina do obróbki tynku
GB201812861D0 (en) Methods of administering therapy
IL289069A (en) Synergistic effect of fxr and ifn agonist for treatment of HBV infection
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
HK40102383A (zh) Hbv疫苗和治疗hbv的方法
HK40119384A (zh) Hbv疫苗和治疗hbv的方法
HK40113589A (zh) Hbv疫苗和治疗hbv的方法
GB202315114D0 (en) Viral treatment
HK40068232A (en) Therapeutic viral vaccine
HK40052943A (en) Combination therapy for treating hepatitis b virus infection